| DB ID | MyCo_2966 |
| Title | Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints |
| Year | 2012 |
| PMID | 22634880 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis is a common and fre- quently lethal infectious syndrome. Despite advances in diagnostics and therapeutics, the mortality is ap- proximately 50%. There are increasing reports of triazole resistance in Aspergillus fumigatus and this appears to be associated with increased mortality. Relatively little is known about the pharmacodynamics (PD) of antifungal agents against Aspergillus spp. A better understanding represents an important step toward improved clinical outcomes for patients. |
| Technique | ELISA |
| Analysis Method | FDA Approved -Platelia Aspergillus ELISA |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA, Platelia Aspergillus; Bio-Rad, Edmonds, WA) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
